RP - HPLC Method Development and Validation for Simultaneous Estimation of Pyrantel Pamoate, Praziquantel, Febantel in Tablet

A simple, rapid, economical, precise and accurate RP-HPLC method for simultaneous estimation of praziquantel, pyrental pamoate and febantel in their combined dosage form has been developed. A validated RP-HPLC method for simultaneous estimation of pyrental pamoate, praziquantel, febantel in tablet dosage form has been developed. The separation was achieved by C18 column (250 x 4.6mm, 5µm particle size) with mobile phase of Buffer: ACN (60:40% v/v) pH 3.0, at a flowrate of 1mL/min and effluent was monitored at 240nm using PDA detector. Retention time of praziqunatel, pyrental pamoate and febantel was found to be 2.587 min, 5.970 min and 8.401 min respectively. The method has been validated for linearity, accuracy, precision, specificity, limit of detection and limit of quanitzation. Linearity was found in the range of 6.25-18.75 µg/ml, 18-54 µg/ml and 18.75-56.25 µg/ml for praziquantel, pyrental pamoate and febantel. The recoveries for praziquantel, pyrental pamoate and febantel were found to be 99.76 ± 0.211%, 99.77 ± 0.490% and 99.61± 0.241 respectively in tablet. The percentage assay of three drugs were found to be 96.82%,97.66% and 96.92% for Praziquantel, Pyrental pamoate and Febantel respectively. Developed method was found to be new, accurate, precise and robust for simultaneous estimation of praziquantel, pyrental pamoate and febantel in tablet dosage form. The proposed method enables rapid quantification and simultaneous analysis of three drugs from commercial formulations without any excipients interference.